Age-related macular degeneration (AMD) is the leading cause of visual impairment in industrialized countries. Anatomical examination findings at the early and intermediate stages of AMD are not sufficient to determine any functional alterations at these stages (e.g., alterations in microperimetry, multifocal electroretinogram (mfERG) and contrast sensitivity). Identifying early functional markers of the disease is a necessary first step in the development and clinical validation of treatments to slow progression to advanced disease.
Patient over 18 years of age
Corrected visual acuity 10/10 in each eye
Conventional "soft" or "hard" drusen
Cuticular drusen
Presence of geographic atrophy, even incipient, in one or both eyes
Presence of patent or latent neovascularization visible on OCT b-scan or OCT-A in one or both eyes
Compatibility of retinal signs with a "probable" differential diagnosis (bestrophinopathies, familial drusen, fundus flavimaculatus, fundus albipunctatus, hypovitaminosis A) in one or both eyes.
Oculomotor pathology that may prevent proper performance of functional tests: nystagmus, oculomotor paralysis, in one or both eyes
subjects with early or intermediate AMD (normal visual acuity)
Cohort
Prospective
Not listed
AMD evolution at 4 years
AMD is considered to have progressed if, after 4 years, the patient has developed an advanced form of the disease. The onset of an advanced form is defined by the appearance of macular neovascularization (of any type), visible on fundus or OCT/OCT-A, or by the appearance of macular atrophy visible on fundus, autofluorescence or OCT.
Click on the lead sponsor to view all of their trials.
